ArticleInternational journal of nanomedicine2017
Improved LFIAs for highly sensitive detection of BNP at point-of-care.
Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 54 citations in OpenAlex.
- Point-of-Care Diagnostics Using Self-heating Elements from Smart Food Packaging: Moving Towards Instrument-Free Nucleic Acid-Based Detection.Molecular diagnosis & therapy · 2025Review
- Point-of-care diagnostic devices for periodontitis - current trends and urgent need.Sensors & diagnostics · 2024Review
- Gold Nanotapes and Nanopinecones in a Quantitative Lateral Flow Assay for the Cancer Biomarker Carcinoembryonic Antigen.ACS applied nano materials · 2023Article
- Enhancing a SARS-CoV-2 nucleocapsid antigen test sensitivity with cost efficient strategy through a cotton intermembrane insertion.Scientific reports · 2023Article
- Economical and Easily Obtainable Tools to Manually Develop Lateral Flow Immunoassay Strips.ACS omega · 2023Article
- Affordable on-site COVID-19 test using non-powered preconcentrator.Biosensors & bioelectronics · 2023Article
- Ultrasensitive dynamic light scattering immunosensing platform for NT-proBNP detection using boronate affinity amplification.Journal of nanobiotechnology · 2022Article
- Recent Progress in Nanotechnology for COVID-19 Prevention, Diagnostics and Treatment.Nanomaterials (Basel, Switzerland) · 2021Review
- Emerging point-of-care biosensors for rapid diagnosis of COVID-19: current progress, challenges, and future prospects.Analytical and bioanalytical chemistry · 2021Review
- Development of Point-of-Care Biosensors for COVID-19.Frontiers in chemistry · 2020Review
- Towards Point-of-Care Heart Failure Diagnostic Platforms: BNP and NT-proBNP Biosensors.Sensors (Basel, Switzerland) · 2019Review
- Emerging Point-of-care Technologies for Food Safety Analysis.Sensors (Basel, Switzerland) · 2019Review
- Article
- Optimized Lateral Flow Immunoassay Reader for the Detection of Infectious Diseases in Developing Countries.Sensors (Basel, Switzerland) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) has become a major cause of morbidity and mortality with a significant global economic burden. Although well-established clinical tests could provide early diagnosis, access to these tests is limited in developing countries, where a relatively higher incidence of HF is present. This has prompted an urgent need for developing a cost-effective, rapid and robust diagnostic tool for point-of-care (POC) detection of HF. Lateral flow immunoassay (LFIA) has found widespread applications in POC diagnostics. However, the low sensitivity of LFIA limits its ability to detect important HF biomarkers (e.g., brain natriuretic peptide [BNP]) that are normally present in low concentration in blood. To address this issue, we developed an improved LFIA by optimizing the gold nanoparticle (GNP)-antibody conjugate conditions (e.g., the conjugate pH and the amount of added antibody), the diameter of GNP and the concentration of antibody embedded on the test line and modifying the structure of test strip. Through these improvements, the proposed test strip enabled the detection of BNP down to 0.1 ng/mL within 10-15 min, presenting ~15-fold sensitivity enhancement over conventional lateral flow assay. We also successfully applied our LFIA in the analysis of BNP in human serum samples, highlighting its potential use for clinical assessment of HF. The developed LFIA for BNP could rapidly rule out HF with the naked eye, offering tremendous potential for POC test and personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.